222 related articles for article (PubMed ID: 36539508)
21. Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer.
Matsubara N; Nagamori S; Wakumoto Y; Uemura H; Kimura G; Yokomizo A; Kikukawa H; Mizokami A; Kosaka T; Masumori N; Kawasaki Y; Yonese J; Nasu Y; Fukasawa S; Sugiyama T; Kinuya S; Hosono M; Yamaguchi I; Tsutsui H; Uemura H
Int J Clin Oncol; 2018 Feb; 23(1):173-180. PubMed ID: 28770408
[TBL] [Abstract][Full Text] [Related]
22. Bone-related Parameters are the Main Prognostic Factors for Overall Survival in Men with Bone Metastases from Castration-resistant Prostate Cancer.
Fizazi K; Massard C; Smith M; Rader M; Brown J; Milecki P; Shore N; Oudard S; Karsh L; Carducci M; Damião R; Wang H; Ying W; Goessl C
Eur Urol; 2015 Jul; 68(1):42-50. PubMed ID: 25449207
[TBL] [Abstract][Full Text] [Related]
23. Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial.
Saad F; Carles J; Gillessen S; Heidenreich A; Heinrich D; Gratt J; Lévy J; Miller K; Nilsson S; Petrenciuc O; Tucci M; Wirth M; Federhofer J; O'Sullivan JM;
Lancet Oncol; 2016 Sep; 17(9):1306-16. PubMed ID: 27473888
[TBL] [Abstract][Full Text] [Related]
24. Bone Scan Index predicts outcome in patients with metastatic hormone-sensitive prostate cancer.
Poulsen MH; Rasmussen J; Edenbrandt L; Høilund-Carlsen PF; Gerke O; Johansen A; Lund L
BJU Int; 2016 May; 117(5):748-53. PubMed ID: 25906907
[TBL] [Abstract][Full Text] [Related]
25. 223Ra Therapy in Patients With Advanced Castration-Resistant Prostate Cancer With Bone Metastases: Lessons from Daily Practice.
van der Doelen MJ; Kuppen MCP; Jonker MA; Mehra N; Janssen MJR; van Oort IM; Gerritsen WR
Clin Nucl Med; 2018 Jan; 43(1):9-16. PubMed ID: 29166331
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of two-dimensional total bone uptake (2D-TBU) and bone scan index (BSI) extracted from active bone metastatic burden on the bone scintigraphy in patients with radium-223 treatment.
Fukai S; Daisaki H; Umeda T; Shimada N; Terauchi T; Koizumi M
Ann Nucl Med; 2024 Jun; 38(6):450-459. PubMed ID: 38517659
[TBL] [Abstract][Full Text] [Related]
27. A qualitative research study in Japan investigating patients' experience with metastatic castration-resistant prostate cancer: from diagnosis to decision for Ra-223 treatment.
Akakura K; Uemura H; Miyazaki K; Stroupe A; Seo C; Uzumcu A; Ledesma DA
Future Oncol; 2021 Dec; 17(36):5103-5118. PubMed ID: 34664992
[TBL] [Abstract][Full Text] [Related]
28. Initial Experience With Radium-223 Chloride Treatment at the Kanazawa University Hospital.
Nakashima K; Makino T; Kadomoto S; Iwamoto H; Yaegashi H; Iijima M; Kawaguchi S; Nohara T; Shigehara K; Izumi K; Kadono Y; Matsuo S; Mizokami A
Anticancer Res; 2019 May; 39(5):2607-2614. PubMed ID: 31092459
[TBL] [Abstract][Full Text] [Related]
29. Patterns of response and progression in bone and soft tissue during and after treatment with radium-223 for metastatic castrate-resistant prostate cancer.
McNamara MA; Oyekunle T; Chin BB; Oldan J; Anand A; Ritz M; Shantzer L; Anand M; Armstrong AJ; George DJ
Prostate; 2019 Jul; 79(10):1106-1116. PubMed ID: 31045266
[TBL] [Abstract][Full Text] [Related]
30. Safety and efficacy of radium-223 dichloride in Japanese patients with castration-resistant prostate cancer and bone metastases.
Uemura H; Uemura H; Matsubara N; Kinuya S; Hosono M; Yajima Y; Doi T
Int J Clin Oncol; 2017 Oct; 22(5):954-963. PubMed ID: 28478485
[TBL] [Abstract][Full Text] [Related]
31.
Dizdarevic S; Jessop M; Begley P; Main S; Robinson A
Eur J Nucl Med Mol Imaging; 2018 Dec; 45(13):2264-2273. PubMed ID: 29998419
[TBL] [Abstract][Full Text] [Related]
32. Bone scan index can be a useful biomarker of survival outcomes in patients with metastatic castration-resistant prostate cancer treated with radium-223.
Naito M; Ukai R; Hashimoto K
Cancer Rep (Hoboken); 2019 Oct; 2(5):e1203. PubMed ID: 32721117
[TBL] [Abstract][Full Text] [Related]
33. Validation of the 3-variable prognostic score (3-PS) in mCRPC patients treated with
Frantellizzi V; Monari F; Mascia M; Costa R; Rubini G; Spanu A; Di Rocco A; Lodi Rizzini E; Cindolo L; Licari M; Lavelli V; Nuvoli S; De Angelis C; Dionisi V; Ferrari C; De Vincentis G
Ann Nucl Med; 2020 Oct; 34(10):772-780. PubMed ID: 32654030
[TBL] [Abstract][Full Text] [Related]
34. Novel nomograms for castration-resistant prostate cancer and survival outcome in patients with de novo bone metastatic prostate cancer.
Zhao J; Sun G; Liao B; Zhang X; Armstrong CM; Yin X; Liu J; Chen J; Yang Y; Zhao P; Tang Q; Wang Z; Chen Z; Li X; Wei Q; Li X; Chen N; Gao AC; Shen P; Zeng H
BJU Int; 2018 Dec; 122(6):994-1002. PubMed ID: 29772102
[TBL] [Abstract][Full Text] [Related]
35. Three-year follow-up of a phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer and bone metastases.
Uemura H; Uemura H; Nagamori S; Wakumoto Y; Kimura G; Kikukawa H; Yokomizo A; Mizokami A; Kosaka T; Masumori N; Kawasaki Y; Yonese J; Nasu Y; Fukasawa S; Sugiyama T; Kinuya S; Hosono M; Yamaguchi I; Akagawa T; Matsubara N
Int J Clin Oncol; 2019 May; 24(5):557-566. PubMed ID: 30875000
[TBL] [Abstract][Full Text] [Related]
36. Early alkaline phosphatase dynamics as biomarker of survival in metastatic castration-resistant prostate cancer patients treated with radium-223.
van der Doelen MJ; Stockhaus A; Ma Y; Mehra N; Yachnin J; Gerritsen WR; Nilsson S; van Oort IM; Ullén A
Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3325-3334. PubMed ID: 33686456
[TBL] [Abstract][Full Text] [Related]
37. Administration of radium-223 and the prognosis in Japanese bone metastatic castration-resistant prostate cancer patients: A large database study.
Kawahara T; Miyoshi Y; Ninomiya S; Sato M; Takeshima T; Hasumi H; Makiyama K; Uemura H
Int J Urol; 2022 Sep; 29(9):1079-1084. PubMed ID: 35976620
[TBL] [Abstract][Full Text] [Related]
38. Impact of pre-treatment variables on the completion of
Lavelli V; Nappi AG; Caputo P; Asabella AN; Fanelli M; Sardaro A; Altini C; Ferrari C; Rubini G
Hell J Nucl Med; 2019; 22 Suppl 2():153-163. PubMed ID: 31802056
[TBL] [Abstract][Full Text] [Related]
39. Patient Selection for Radium-223 Therapy in Patients With Bone Metastatic Castration-Resistant Prostate Cancer: New Recommendations and Future Perspectives.
van der Doelen MJ; Mehra N; Hermsen R; Janssen MJR; Gerritsen WR; van Oort IM
Clin Genitourin Cancer; 2019 Apr; 17(2):79-87. PubMed ID: 30558834
[TBL] [Abstract][Full Text] [Related]
40. [Role of Bone Scan Index (BSI) in the Prognosis and Treatment Efficacy in Castration-Sensitive Prostate Cancer Patients with Bone Metastasis].
Deguchi K; Sasaki T; Oue H; Okamoto T; Kato M; Kajiwara S; Higashi S; Masui S; Nishikawa K; Inoue T
Hinyokika Kiyo; 2024 Feb; 70(2):29-37. PubMed ID: 38447942
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]